期刊文献+

心脏再同步治疗术后患者死亡原因分析 被引量:1

Cause of death in patients with heat failure after cardiac resynchronization therapy
原文传递
导出
摘要 目的探讨心力衰竭患者心脏再同步治疗(CRT)术后的死亡原因及相关影响因素。方法对110例行CRT的心力衰竭患者[其中7例植入带有心脏再同步治疗除颤器(CRT—D)]进行长期随访,观察患者术后的转归情况,以及死亡患者的死亡原因、生存时间和相关影响因素。结果110例患者中有92例患者完成随访研究,随访1~132(48±28)个月,共死亡30例,死亡率为32.6%,5年生存率为66.9%±5.8%。24例为心脏性死亡,占总体死亡的80%,其中包括11例为心力衰竭恶化导致的死亡,13例为心脏性猝死(SCD),其余6例为非心脏性死亡。14例行CRT的持续性心房颤动(房颤)患者中有8例死亡;71例行CRT的窦性心律患者中死亡22例;前组的中位生存时间短于后组(50比87,P=0.013);7例植人CRT—D的患者均无死亡;3组患者的死亡率差异有统计学意义(P=0.01)。合并慢性肾功能衰竭的CRT患者死亡率(66.7%)较无肾功能不良者(20.6%)高(相对危险度:3.24,95%CI1.88~5.59,P〈0.001)。结论CRT患者的主要死亡原因是心脏性死亡,其中包括心力衰竭恶化和SCD。CRT—D和CRT两组患者之间的死亡率差异有统计学意义,接受CRT的窦性心律患者较持续性房颤患者有显著的生存获益。合并慢性肾功能衰竭的CRT患者预后较差。对于合并持续性房颤的CRT患者同时给予房室结消融有可能进一步提高生存率。 Objective The aim of this study was to explore the cause of and the factors related to death in patients with heart failure (HF) after cardiac resynchronization therapy(CRT). Methods One hundred and ten patients with congestive heart failure treated with CRT were enrolled in this study, including 7 patients underwent CRT+an implantable defibrillator(CRT-D). The postoperative outcome,cause of death, survival time, as well as the factors related to death were observed during the long follow-up. Results The mean follow-up period was 1 -132(48+28)months, while 92 patients have completed the follow-up. Thirty patients died (32.6%), and the 5-year survival rate was 66. 9% - 5.80/o. Twenty-four of them (80%) were cardiac causes (pump failure = 11 , sudden cardiac death = 13 ) , and 6 patients due to non-cardiac causes. Eight patients with persistent atrial fibrillation(n= 14) died,22 patients with sinus rhythm (n = 71 ) died, all patients with sinus rhythm who underwent CRT-D ( n = 7) were survival. There were significant differences ( P = 0. 01 ) in the mortality among the three groups. The mortality in patents with chronic renal failure (CRF) was higher than those without CRF ( HR : 3.24,95% CI 1.88 - 5.59, P〈0. 001 ). Conclusion Cardiac death, including heart pump failure and sudden cardiac death are the predominant causes of death in patients 'after CRT. Patients with persistent atrial fibrillation or CRF have disadvantage in survival. CRT-D improve survival rate,and atrio-ventricular node ablation in patients with persistent atrial fihrillation may he a way to improve survival rate.
出处 《中华心律失常学杂志》 2011年第4期288-291,共4页 Chinese Journal of Cardiac Arrhythmias
关键词 心脏再同步治疗 死亡原因 心力衰竭 心脏性猝死 Cardiac resynchronization therapy Cause of death Heart failure Sudden cardiac death
  • 相关文献

参考文献18

  • 1Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association Class IV heart failure. Circulation ,2007,115:204-212.
  • 2John Sutton MS, Ghio S, Plappert T, et al. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association Class I/ II heart failure. Circulation ,2009,120 : 1858-1865.
  • 3Yu CM, Fung JW, Zhang Q, et al. Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy. Circulation, 2004, 110:66-73.
  • 4McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart ,2000,83:596-602.
  • 5Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N En J Med,2005,352 : 1539-1549.
  • 6Carson P,Anand I, O' Connor C,et al. Mode of death in advanced heart failure. The Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) Trial. J Am Coll Cardiol, 2005,46 : 2329-2334.
  • 7Rivero-Ayerza M, Theuns DAM J, Garcia-Garcia HM, et al. Effects of cardiac resynchronization therapy on overall mortality and mode of death : a meta-analysis of randomized controlled trials. Eur Heart J, 2006,27 : 2682 -2688,.
  • 8Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [ the Cardiac Resynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J,2006,27:1928-1932.
  • 9Dickstein K, Vardas PE, Auricchio A, et al. 2010 focused update of ESC guidelines on device therapy in heart failure : an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Europace,2010,12 : 1526-1536.
  • 10Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol,2003,91:2D-8D.

同被引文献24

  • 1Higgins SL, Hummel JD, Niazi IK, et al.Cardiac resynchronizationtherapy for the treatment of heart failure in patients with intravent-ricular conduction delay and malignant ventricular tachyarrhyth-mias.J Am Coll Cardiol,2003,42: 1454-1459.
  • 2Young JB,Abraham WT,Smith AL,et al.Combined cardiac resyn-chronization and implantablecardioversion defibrillation in advancedchronic heart failure : the MIRACLE ICD Trial. JAMA, 2003,289 :2685-2694.
  • 3Abraham WT, Young JB,Leon AR,et al.Effects of cardiac resyn-chronization on disease progression in patients with left ventricularsystolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circula-tion,2004,110;2864-2868.
  • 4Bristow MR,Saxon LA,Boehmer J,et al.Cardiac-resynchronizationtherapy with or without an implantable defibrillator in advancedchronic heart failure.N Engl J Med ,2004,350 : 2140- 2150.
  • 5Linde C,Abraham WT,Gold MR,et al.Randomized trial of cardiacresynchronization in mildly symptomatic heart failure patients andin asymptomatic patients with left ventricular dysfunction and previ-ous heart failure symptoms. J Am Coll Cardiol, 2008, 52: 1834-1843.
  • 6Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronizationtherapy for the prevention of heart-failure events. N Engl J Med,2009,361:1329-1338.
  • 7Tang AS,Wells GA,Talajic M,et al. Cardiac-resynchronizationtherapy for mild-to-moderate heart failure. N Engl J Med,2010,363:2385-2395.
  • 8McMurray JJ, Adamopoulos S, Anker SD,et al.ESC Guidelines forthe diagnosis and treatment of acute and chronic heart failure2012: The Task Force for the Diagnosis and Treatment of Acuteand Chronic Heart Failure 2012 of the European Society of Cardi-ology. Developed in collaboration with the Heart Failure Association(HFA)of the ESC.Eur Heart J,2012,33:1787-1847.
  • 9Epstein AE,Dimarco JP,Ellenbogen KA,et al.2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Ab-normalities :A Report of the American College of Cardiology Foun-dation/American Heart Association Task Force on Practice Guide-lines and the Heart Rhythm Society.Circulation,2013,127:e283-352.
  • 10vanVeldhuisen DJ, Maass AH, Priori SG,et al. Implementation ofdevice therapy (cardiac resynchronization therapy and implantablecardioverter defibrillator) for patients with heart failure in Europe :changes from 2004 to 2008. Eur J Heart Fail, 2009, 11: 1143-1151.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部